Indication
Cachexia due to HIV
Cachexia due to human immunodeficiency virus (HIV)—historically categorized as HIV wasting syndrome—is a systemic metabolic and catabolic complication affecting individuals with HIV infection, most frequently observed in advanced disease or uncontrolled viremia. Read more about Cachexia due to HIV
19 drugs 18 manufacturers
Drugs that treat it
Common Cachexia due to HIV therapies.
MEGESTROL ACETATE
MEGESTROL ACETATE
MEGESTROL ACETATE
MEGESTROL ACETATE
MEGESTROL ACETATE
MEGESTROL ACETATE
MEGESTROL ACETATE
MEGESTROL ACETATE
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonCachexia due to human immunodeficiency virus (HIV)—historically categorized as HIV wasting syndrome—is a systemic metabolic and catabolic complication affecting individuals with HIV infection, most frequently observed in advanced disease or uncontrolled viremia.
It predominantly impacts the musculoskeletal and metabolic systems, presenting clinically as severe, involuntary weight loss characterized by a disproportionate depletion of lean body mass and skeletal muscle, often accompanied by persistent diarrhea, weakness, or fever lasting at least 30 days.
Pathophysiologically, the condition is driven by sustained immune dysregulation and elevated proinflammatory cytokines—such as tumor necrosis factor-alpha and interleukin-6—which induce hypermetabolism, altered protein synthesis, and anorexia, frequently exacerbated by enteropathy and nutrient malabsorption.
- nih.gov
Cachexia due to human immunodeficiency virus (HIV)—historically categorized as HIV wasting syndrome—is a systemic metabolic and catabolic complication affecting individuals with HIV infection, most frequently observed in advanced disease or uncontrolled viremia
- thebody.com
Cachexia due to human immunodeficiency virus (HIV)—historically categorized as HIV wasting syndrome—is a systemic metabolic and catabolic complication affecting individuals with HIV infection, most frequently observed in advanced disease or uncontrolled viremia
- nih.gov
It predominantly impacts the musculoskeletal and metabolic systems, presenting clinically as severe, involuntary weight loss characterized by a disproportionate depletion of lean body mass and skeletal muscle, often accompanied by persistent diarrhea, weakness, or fever lasting at least 30 days Pathophysiologically, the condition is driven by sustained immune dysregulation and elevated proinflammatory cytokines—such as tumor necrosis factor-alpha and interleukin-6—which induce hypermetabolism, a...
- nih.gov
It predominantly impacts the musculoskeletal and metabolic systems, presenting clinically as severe, involuntary weight loss characterized by a disproportionate depletion of lean body mass and skeletal muscle, often accompanied by persistent diarrhea, weakness, or fever lasting at least 30 days
- nih.gov
Pathophysiologically, the condition is driven by sustained immune dysregulation and elevated proinflammatory cytokines—such as tumor necrosis factor-alpha and interleukin-6—which induce hypermetabolism, altered protein synthesis, and anorexia, frequently exacerbated by enteropathy and nutrient malabsorption
Personalize your experience
Follow Cachexia due to HIV and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.